Clearmind Medicine Inc. · NASDAQ:CMND
Clearmind Medicine — Investor Presentation (October 2024)
19 slides from Clearmind Medicine's investor presentation, October 2024
Slide 1: Novel Psychedelics for Treating Addictions, Obesity & Mental Health
Novel Psychedelics for Treating Addictions, Obesity & Mental Health Corporate Presentation | October 2024 NASDAQ: CMND FSE: CWY0 www.Clearmindmedicine.com Clearmind Medicine Inc.
Slide 2: Disclaimer and Forward-Looking Statements
Disclaimer and Forward-Looking Statements All statements in this presentation, other than those relating to historical facts, are "forward-looking statements.” Forward-looking statements contained in this presentation include, but are not limited to, statements regarding Clearmind Medicine Inc. (the
Slide 3: About Clearmind
About Clearmind Why Psychedelics? Psychedelic compounds are increasingly being studied and many believe represent the future for treatment of a variety of mental health disorders. Clearmind’s solutions for addiction, especially alcoholism and obesity, hold the potential to better the lives of millio
Slide 4: Pipeline
Pipeline Clearmind Medicine Inc. Corporate Presentation | October 2024 Page 4
Slide 5: Alcohol Use Disorder
Alcohol Use Disorder Clearmind’s flagship treatments are focused on Alcohol Use Disorder (AUD), which is extremely common. AUD describes a person’s inability to restrict their alcohol consumption, despite negative social, occupational, or health consequences. Alcohol consumption contributes to 2.6 m
Slide 6: The Opportunity
The Opportunity Only 4 FDA approved medicines for AUD The yearly cost of excessive Approved by FDA Average $/Month alcohol use in the US was Antabuse Disulfiram 1949 $42 almost $250 billion in 2010 https://pubmed.ncbi.nlm.nih.gov/26477807/ Campral 2004 $125 Acamprosate ReVia 1994 $205 Naltrexone $28
Slide 7: Clearmind's solution is its flagship proprietary molecule: MEAI
Clearmind’s solution is its flagship proprietary molecule: MEAI or 5-Methoxy-2-aminoindane O NH2 MEAI is a non-hallucinogenic Holds the potential to change In recreational use, exerted a reduced Believed to impart a feeling of psychoactive molecule the lives of millions who desire to consume alcohol
Slide 8: Successful pre-clinical results in MEAI treatment for alcohol consumption
Successful pre-clinical results in MEAI treatment for alcohol consumption Pre-clinical trials demonstrated high safety profile in addition to a significant and immediate reduction effect on alcohol consumption. Clearmind Medicine Inc. Corporate Presentation | October 2024 Page 8
Slide 9: Clearmind's First In-Human Clinical Trials: CMND-100 for AUD
Clearmind’s First In-Human Clinical Trials: CMND-100 for AUD Study design: Clinical Sites: Phase I/IIa The IIa will be a double-blind, placebo-controlled study • Yale School of Medicine’s Primary end point: to find the tolerable dose and characterize the safety and Department of Psychiatry pharmacok
Slide 10: Obesity & Metabolic Syndrome
Obesity & Metabolic Syndrome The global obesity market size is about $29.5B and expected to grow to $31.7B by 2030. The global metabolic syndrome market was valued at $62B in year 2021 and is expected to grow to up to $110.5B by 2029. Patent application filed with the USPTO. Positive pre-clinical re
Slide 11: Pre-clinical results in treating Obesity
Pre-clinical Pre-clinical results in treating Obesity results in • Led by Prof. Joseph Tam, DMD, PhD, head of the Obesity and Metabolism Laboratory and Associate Professor of Pharmacology at the Hebrew treating Obesity University’s Institute for Drug Research and Dr. Saja Baraghithy, PhD. • 3 groups
Slide 12: Competitive Advantages
Competitive Advantages Clearmind is one of the few companies focused on binge behaviors and addictions: a Focusing on alcoholism, huge untapped market. MEAI is potentially effective for alcoholism, cocaine addiction weight loss & addictions and obesity. Novel, proprietary Clearmind is the sole globa
Slide 13: Alcohol Substitute Program
Alcohol Substitute Program The global market size for no- and low-alcohol beverages estimated at over $13B in 2023 1 • Alcohol substitute was granted patents in the USA, Europe and India • Completed most of the pre-clinical studies required for a novel-food application submission according to novel
Slide 14: IP Portfolio
IP Portfolio: MEAI: 2 mature families for binge behaviour regulators and alcoholic beverage substitute MEAI + PEA: 4 families for combination treatment for binge behaviour, cocaine addiction, obesity and metabolic 29 granted patents syndrome, and depression in major jurisdictions such as USA, EU, 6
Slide 15: Team of International Experts
Team of International Experts Adi Zuloff-Shani, PhD Alan Rootenberg Mark Haden, MSW Gadi Levin, MBA Chief Executive Officer Chief Financial Officer VP Business Development VP Finance Sara Horn, PhD Nick Kadysh Yael Stav, PhD Adi Varon Clinical and Regulatory Special Advisor Program Management Contro
Slide 16: Highly Accomplished Board of Directors
Highly Accomplished Board of Directors Amitay Weiss Oz Adler Yehonatan Shachar Asaf Itzhaik Hila Kiron-Revach Chairman of the Board Director Director Director Director Mr. Weiss served as the Chief Executive Officer of Mr. Oz Adler has served as our Director since Mr. Yehonatan Shachar has served as
Slide 17: Award-Winning Advisory Board
Award-Winning Advisory Board Prof. John Krystal Prof. Fatima Stanford Prof. Henry R. Kranzler Prof. Alon Friedman Prof. Christian Schütz MD , Yale University, CT, MD, MPH, MPA, Harvard Medical MD, PhD, University of Pennsylvania, MD, PhD, Dalhousie University, MD, PhD, University of British US Schoo
Slide 18: Upcoming Milestones
Upcoming Milestones Clinical trial initiation CMND- 100 for treating Alcohol Use Disorder Initiate Israeli site and two US sites: Johns Hopkins and Yale University Expanding strategic collaborations Continue pre-clinical studies for obesity Continue to develop MEAI-based alcohol substitute for consu
Slide 19: Let's make history together.
Let's make history Join our journey together. Investor Relations US: CMND@crescendo-IR.com invest@clearmindmedicine.com clearmindmedicine.com Clearmind Medicine Inc. Corporate Presentation | October 2024 Page 19
Clearmind Medicine — Investor Presentation (October 2024) on 6ix